# Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer

> **NCT01605305** · PHASE2 · COMPLETED · sponsor: **Fudan University** · enrollment: 60 (actual)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** FOLFOX6

## Key facts

- **NCT ID:** NCT01605305
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2012-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01605305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01605305, "Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01605305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*